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Abstract
Background: We examined whether body mass index (BMI) changes in adulthood, 
prior to disease onset, are associated with overall survival among esophageal adeno-
carcinoma patients.
Methods: We included 285 histologically confirmed patients with a complete base-
line BMI questionnaire. Using extended Cox regression models, we obtained ad-
justed hazard ratios (HRs) for the associations between overall survival and BMI 
at diagnosis, BMI 6 months before diagnosis, self-reported average adult BMI, and 
ΔBMI (BMI 6 months before diagnosis minus average adult BMI), categorized into 
tertiles <0 kg/m2 (BMI loss), ≥0 and <1.25 kg/m2 (stable BMI), and ≥1.25 kg/m2 
(BMI gain). We also assessed interaction between ΔBMI and average adult BMI 
(≥ kg/m2 versus <27.5 kg/m2) with overall survival.
Results: Body mass index at diagnosis >25 and <35  kg/m2 was associated with 
better overall survival. Compared to patients with stable BMI in adulthood, patients 
who gained BMI throughout adulthood had 1.68 times the all-cause hazard of death 
(95% CI: 1.17-2.43; P < .01), independent of diagnosis BMI and percent weight loss 
6 months before diagnosis. Compared to patients with average adult BMI < 27.5 who 
maintained stable adult BMI, patients with average adult BMI ≥ 27.5 kg/m2 who 
gained BMI had the worst survival (HR = 3.05; 95% CI 1.62-5.72; P < .01).
Conclusion: Body mass index gain in adulthood is associated with poor overall sur-
vival, and maintaining a normal body weight throughout adulthood is associated with 
the best overall survival among esophageal adenocarcinoma patients, independent of 
BMI at diagnosis.
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1 |  INTRODUCTION
Esophageal adenocarcinoma (EA) is the most common his-
tological subtype of esophageal cancer in the western world, 
and fewer than 20% of patients survive 5  years.1 As with 
many cancer sites, obesity, measured as body mass index 
(BMI) > 30 kg/m2, is an established risk factor for EA,2-7 but 
also as for many other cancer sites, the relationship of BMI 
and EA survival is less clear. To date, most studies of BMI as 
a prognostic marker in EA have focused on change in weight 
after esophagectomy or compared pretreatment weight to 
posttreatment weight. The results have been mixed, either in-
dicating no association with BMI on survival time8-15 or that 
patients with higher BMI have better overall survival.15-19 
However, higher BMI at diagnosis (d-BMI) and during treat-
ment may in part indicate better overall health and lead to 
reverse causation of associations with overall survival in 
studies of postdiagnosis BMI.20,21
Few studies have examined weight or weight change prior 
to disease onset as a prognostic factor in EA. BMI 1  year 
prior to diagnosis is not associated with overall survival.22,23 
Yet, one study showed that high BMI in early adulthood (age 
18-25) was associated with worse overall survival in EA.22 
Additionally, substantial weight loss (>10% of body weight), 
after disease onset, in the months leading to diagnosis has 
been associated with poor overall survival in EA.22,24
An estimated 80% of esophageal cancer patients report 
some weight loss in the 6 months prior to diagnosis,25,26 but 
since high BMI is a strong risk factor for EA, most patients 
are nevertheless overweight or obese at the time of diagnosis 
despite the weight loss. Moreover, many patients have expe-
rienced in weight changes in adulthood separate from can-
cer-related weight loss. Clinically, considering BMI from a 
single time point (eg, diagnosis) conflates patients who have 
had dynamic weight in adulthood prior to disease onset, 
patients with disease-related weight loss, and patients who 
have had stable adult weight. To date, patients' adult weight 
changes prior to disease onset have not been considered as a 
prognostic factor. These weight changes may carry indepen-
dent risks or benefits to disease outcomes and may help to 
elucidate the previously reported “obesity paradox” in EA.
Therefore, we examined whether changes in BMI in adult-
hood, prior to disease onset, were associated with overall sur-
vival among EA patients. Adult BMI (a-BMI), d-BMI, and 
weight change are three unique facets with potentially differ-
ent associations with overall survival. Thus, to improve our 
understanding of the pattern of association with survival and 
BMI at different times, we first studied the association be-
tween overall survival and BMI at d-BMI, BMI 6 months be-
fore diagnosis (BMI-6mo), and self-reported average a-BMI. 
We then assessed the change from average a-BMI to BMI-
6mo (ΔBMI) on overall survival time in EA patients. Finally, 
we hypothesized that a-BMI changes may have different 
associations with survival depending on patients' starting 
BMI, so we tested whether the association with ΔBMI and 
overall survival in EA was modified by average a-BMI.
2 |  METHODS
2.1 | Study population
The Molecular Epidemiology of Esophageal Cancer27,28 
is an ongoing study of esophageal cancer patients from 
Massachusetts General Hospital (MGH), which began recruit-
ment in January 1999. Recruited patients were >18 years of 
age with a histologically confirmed diagnosis who presented 
to the thoracic oncology or thoracic surgery units at MGH. 
The study protocol was approved by the institutional review 
boards at the Harvard T.H. Chan School of Public Health 
and MGH. Written informed consent was obtained from all 
patients prior to study participation. At the time of enroll-
ment, a trained interviewer obtains patients' demographic 
and lifestyle information through a questionnaire. Since 
September 2004, the patient questionnaire included ques-
tions on weight throughout adulthood. The present study was 
restricted to histologically confirmed EA patients diagnosed 
between 9/1/2004 and 10/31/2016, who received the updated 
questionnaire. We excluded patients who were recruited at 
the time of cancer recurrence or cancer remission, who had 
a concurrent cancer, who only presented to MGH for a sec-
ond opinion, or who were diagnosed with stage 0 disease. 
Of the 407 EA patients who met these criteria, 291 (71.5%) 
had complete information on weight throughout adulthood 
and were included in analyses (Figure S1). Among patients 
included in the study, median time between diagnosis and 
enrollment in the study was 4.8 weeks (IQR 2.1-14.6 weeks). 
We determined patients' diagnosis date, clinical stage, and 
treatment regimen from clinical records.
2.2 | Body mass index measurements
During their questionnaire, patients reported their height, their 
average weight between age 18 and 21  years, their average 
weight between age 21 and 40 years, their average weight past 
the age of 40 years, and their weight loss in the 6 months be-
fore diagnosis, and their weight at time of diagnosis. Weight 
loss 6 months before diagnosis was assumed to be 0 for pa-
tients who did not answer that question but completed all 
other questions about BMI (N = 19). BMI was calculated as 
weight (kg) divided by height squared (m2). d-BMI was based 
on self-reported weight at diagnosis. BMI-6mo was based on 
self-reported weight at diagnosis plus self-reported weight 
lost in the 6 months prior to diagnosis. For patients who were 
45 years or older at time of diagnosis, a-BMI was based on 
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their self-reported average weight past the age of 40 years. For 
patients younger than 45 years old at their time of diagnosis, 
a-BMI was based on their self-reported average weight be-
tween 21 and 40 years (Figure 1). Thus, a-BMI represents av-
erage BMI over a period of at least 5 years prior to diagnosis, 
to capture the association of a-BMI with overall survival, ex-
cluding weight loss that may occur closer to diagnosis, which 
is often related to the cancer. Once calculated, d-BMI, BMI-
6mo, and a-BMI were initially categorized into five groups: 
BMI < 18.5 kg/m2, 18.5 ≤ BMI < 25 kg/m2, 25 ≤ BMI < 30 kg/
m2, 30 ≤ BMI < 35 kg/m2, and BMI ≥ 35 kg/m2. To minimize 
the capture of disease-related weight loss that occurred close 
to diagnosis, ΔBMI was defined as the difference between 
a-BMI and BMI-6mo (Figure 1). We categorized ΔBMI into 
tertiles. The 33rd percentile of ΔBMI was 0  kg/m2 and the 
66th was 1.25 kg/m2. ΔBMI < 0 kg/m2 corresponded to any 
BMI loss; ΔBMI ≥ 0 and <1.25 kg/m2 corresponded to stable 
BMI, which we used as our reference; and ΔBMI ≥ 1.25 kg/
m2 corresponds to BMI gain. Correlations between BMI meas-
urements are presented in Table S1.
2.3 | Overall survival time
Overall survival time was defined as the time from date of 
pathology-confirmed diagnosis until date of death (all-cause 
mortality) or censored at date last known to be alive. Data 
on outcome measures were collected from clinical records 
and hospital cancer registries as well as through public death 
records, and are checked and updated approximately once per 
year. The last vital status update was conducted in August 
2018 before this analysis.
2.4 | Covariates
We modeled crude cigarette smoking history (never, former, 
and current) as an ordinal variable. Cancer stage at diagnosis 
was defined by clinical TNM categories based on American 
Joint Committee on Cancer (AJCC) 8th edition (Table S2), 
but due to the  small number of patients in each stage, for 
analysis we categorized patients has lymph node nega-
tive, lymph node positive, or metastatic disease. Diagnosis 
date was considered date of pathology-confirmed cancer. 
Treatment regimen was modeled as a series of binary vari-
ables: chemotherapy (yes/no), radiation (yes/no), and surgery 
(yes/no). Surgery was modeled as a time-dependent covariate 
for two reasons. First, time between diagnosis and surgery 
is related to prognosis. Patients with early stage tumors re-
ceive esophagectomies as their definitive treatment, whereas 
locally advanced patients will receive esophagectomies 
pending their response to chemotherapy and/or radiation 
treatment. Second, the successful completion of the proce-
dure is the most beneficial treatment for EA patient progno-
sis. Time of chemotherapy and radiation initiation was not 
collected, so we could not model chemotherapy or radiation 
as time-dependent covariates. However, most patients who 
received chemotherapy and radiation did so prior to surgery 
F I G U R E  1  Schematic of exposure variables and their represented time (mo) relative to diagnosis (baseline)
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or as definitive or palliative treatment (Table S3). We also 
adjusted for year of diagnosis to account for slight modifica-
tions to treatment protocols throughout the study period.
2.5 | Statistical models
Predictors of d-BMI and percent loss in body weight 6 months 
before diagnosis were tested using linear regression models. 
We used Kaplan-Meier plots to visualize survival time distri-
butions. Differences in survival curves between groups were 
formally tested using logrank tests. To estimate hazard ratios 
(HRs) of d-BMI, BMI-6mo, a-BMI, and ΔBMI categories on 
overall survival, we used extended Cox regression models, 
adjusting for sex, age at diagnosis, smoking history, year of 
diagnosis, and treatment modality (chemotherapy, radiation, 
and/or surgery) with surgery modeled as a time-dependent 
covariate. We also stratified baseline hazard by clinical stage 
lymph node status at diagnosis because proportional haz-
ards did not hold across stage groups. For the association 
with ΔBMI categories, we ran a second model additionally 
adjusting for d-BMI in addition to the aforementioned vari-
ables, and a third model additionally adjusted for percent 
body weight loss in the 6 months before diagnosis. To as-
sess potential effect modification, we performed an analysis 
testing for interaction between ΔBMI and a-BMI (modeled 
dichotomously as a-BMI ≥ 27.5 versus a-BMI < 27.5). All 
analyses were performed in SAS 9.4(SAS Institute Inc). P-
values were considered significant at a two-sided alpha-level 
of .05.
3 |  RESULTS
Of the 407 eligible patients, 291 EA patients (71.5%) had 
complete BMI information and were included in the anal-
yses (Table  1). Due to  the small number of patients with 
BMI < 18.5 kg/m2 (N = 6), we excluded those patients from 
the main analyses. While the small sample size precludes 
conclusion about associations in this group, we provided the 
same analyses with these six patients included in the supple-
mental material should readers wish to glean the pattern of 
association between body mass variables and overall survival 
for the underweight EA patients. Patients with and without 
complete BMI information did not differ in terms of overall 
survival (HR 1.13, 95% confidence interval [CI] 0.86-1.49, 
P = .38, Figure S2). No patients reported weight gain in the 
6 months prior to diagnosis. About 215 (73.9%) of patients 
reported some weight loss in the 6 months prior to diagnosis 
(median 6.1% loss in body weight [interquartile range 0%-
12.2%]). About 203 patients (69.8%) died during follow-up. 
The median (Kaplan-Meier) survival time for all patients was 
30.7 months (95% CI 26.0-36.1 months).
3.1 | BMI at single time-points
Each percent point of body weight lost in the 6 months be-
fore diagnosis was associated with a 0.18 kg/m2 lower BMI 
T A B L E  1  Demographics of the study population
 
With adult BMI 
available (N = 291)
Without adult BMI 
available (N = 116)
Male 260 (89.4%) 95 (81.9%)
Age 63.1 ± 10.3 64.1 ± 10.2
Race
White 279 (95.9%) 92 (79.3%)
Black 1 (0.3%)  
Hispanic 4 (1.4%) 1 (0.9%)
Asian 1 (0.3%) 2 (1.7%)
Native American 4 (1.4%) 2 (1.7%)
Smoking status
Never 78 (26.8%) 17 (14.7%)
Former 184 (63.2%) 64 (55.2%)
Current 29 (10.0%) 35 (30.2%)
Stage
Lymph node positive 93 (32.0%) 49 (42.2%)
Lymph node negative 127 (43.6%) 56 (48.3%)
Distant metastases 71 (24.4%) 11 (9.5%)
Treatmenta 
Surgery 191 (65.6%) 96 (82.8%)
Radiation 206 (70.8%) 82 (70.7%)
Chemotherapy 240 (82.5%) 86 (74.1%)
Diagnosis BMI (kg/m2)
<18 6 (2.1%) 1 (0.9%)
≥18.5 and <25 81 (27.8%) 30 (25.9%)
≥25 and <30 129 (44.3%) 48 (41.4%)
≥30 and <35 58 (19.9%) 21 (18.1%)
≥35 17 (5.8%) 15 (12.9%)
Average adult BMI (kg/m2)
<18 1 (0.3%)  
≥18.5 and<25 38 (13.1%)  
≥25 and<30 158 (54.3%)  
≥30 and <35 69 (23.7%)  
≥35 25 (8.6%)  
ΔBMI (kg/m2)
<0 79 (27.2%)  
≥0 and <1.25 113 (38.8%)  
≥1.25 99 (34.0%)  
Deaths 203 (69.8%) 68 (58.6%)
Note: Values presented are mean ± standard deviation or absolute number 
(population %).
Abbreviation: BMI, body mass index.
aTreatment categories are not mutually exclusive. 
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at the time of diagnosis (Table S4). Patients who gained BMI 
in adulthood (∆BMI ≥ 1.25 kg/m2) (N = 99) had on aver-
age 3.59 kg/m2 higher d-BMI compared to those with stable 
weight throughout adulthood (N = 113) (P < .01, Table S4).
Overall survival time did not differ by d-BMI in the unad-
justed models (Figure S3: logrank P-value = .08; Table 2). In 
the adjusted model, d-BMI was associated with overall sur-
vival (global Wald P-value = .01, Table 2; Table S6), with 
lowest hazard of death among patients with d-BMI ≥ 25 and 
<35 kg/m2. As a sensitivity analysis to check for potential 
selection bias, we tested the association between overall sur-
vival and d-BMI in the full cohort (Figure S1: N = 407), and 
found a similar pattern of association, though the associa-
tions strengthened in the larger cohort (Table S7).
We found no association between categories of BMI-6mo 
(Figure S4) or a-BMI (Figure S5) and overall survival time 
by logrank test, nor did we find a difference in unadjusted or 
adjusted HRs for categories of BMI-6mo or a-BMI (Table 2; 
Table S6).
3.2 | Percent body weight lost in 6 months 
before diagnosis
Current smokers lost on average 4.79% more body weight in 
the 6 months prior to diagnosis than never smokers (Table S5). 
Patients who lost BMI in adulthood (∆BMI  <  0  kg/m2; 
N = 79) on average had 1.93% less loss in body weight in 
the 6 months before diagnosis (P = .07, Table S5). For each 
percentage point increase in body weight lost in the 6 months 
prior to diagnosis, the all-cause hazard of death for EA pa-
tients increased 1.03 times (95% CI 1.01-1.05; P < .001; data 
not in table).
3.3 | ∆BMI: adult BMI change up to 
6 months before diagnosis
In the unadjusted association of a-BMI change (∆BMI) and 
overall survival, we found no evidence of difference between 
the survival times (Figure  S6). Compared to patients with 
stable a-BMI (N = 111), patients who lost BMI in adulthood 
(N = 75) had 1.16 times the all-cause hazard of death (95% 
CI 0.82-1.63, P = .41), and patients who gained BMI in adult-
hood (N = 99) had 1.32 times the all-cause hazard of death 
(95% CI 0.95-1.83; P =  .10) (data not in table). When ad-
justed for confounders and predictors of overall survival, we 
found patients who gained BMI in adulthood had 1.53 times 
higher all-cause hazard of death compared to patients who 
had stable a-BMI (Table  3, Model 1). The association be-
came more pronounced (HR = 1.68, 95% CI 1.17-2.42) when 
additionally adjusting the model for d-BMI and percent body 
T A B L E  2  Average adult BMI, BMI 6 mo before diagnosis, BMI at the time of diagnosis, and overall survival among EA patients (N = 285)
 
Univariable models Multivariable models
N events/patients
Unadjusted 
HR 95% CI P-value
Global 
P-valuea 
Adjusted 
HRa 95% CI P-value
Global 
P-valueb 
a-BMI categories (kg/m2)
≥18.5 and <25 21/34 Ref     .52 Ref     .68
≥25 and <30 110/157 1.34 0.84; 2.14 .22 1.15 0.71; 1.85 .58
≥30 and <35 48/69 1.47 0.88; 2.46 .14 1.30 0.76; 2.23 .35
≥35 20/25 1.42 0.77; 2.63 .26 1.42 0.74; 2.69 .29
BMI-6mo categories (kg/m2)
≥18.5 and <25 21/30 Ref     .56 Ref     .18
≥25 and <30 87/131 1.05 0.65; 1.69 .85 0.72 0.44; 1.20 .72
≥30 and <35 63/84 1.29 0.79; 2.12 .31 0.97 0.58; 1.62 .97
≥35 28/40 1.21 0.69; 2.14 .51 1.09 0.60; 1.98 .77
d-BMI categories (kg/m2)
≥18.5 and <25 61/81 Ref     .08 Ref     <.01
≥25 and <30 88/129 0.77 0.55; 1.06 .11 0.60 0.42; 0.84 <.01
≥30 and <35 36/58 0.63 0.42; 0.95 .03 0.62 0.41; 0.96 .03
≥35 14/17 1.14 0.64; 2.04 .66 1.22 0.66; 2.42 .53
Abbreviation: BMI, body mass index.
aAdjusted for sex, age at diagnosis, smoking status, treatment and year of diagnosis. The model's baseline hazard was stratified by lymph node status, and surgery was 
a time-dependent covariate. 
bGlobal Wald test with 3 degrees of freedom. Due to small numbers, patients with BMI < 18.5kg/m2 (N = 6) were excluded from these analyses. 
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weight loss 6 months prior to diagnosis (Table 3, Model 3; 
Table S8). Moreover, both d-BMI and percent loss of weight 
in 6 months prior to diagnosis remain significantly associated 
with all-cause hazard of death in the fully adjusted model 
(Table 3, Model 3; Table S8). In these analyses, we did not 
find evidence that patients who lost BMI in adulthood prior 
to disease onset (ΔBMI < 0) had a different all-cause hazard 
of death compared to patients who had stable a-BMI.
3.4 | Interaction between average 
a-BMI and ∆BMI
We examined whether the association between adult weight 
change (∆BMI) and overall survival differed depending on 
patients' average a-BMI. Due to the small number of patients 
who had a-BMI  <  25.0  kg/m2 (N  =  34), we dichotomized 
a-BMI at the half-way point of the overweight category (a-
BMI < 27.5 kg/m2 versus a-BMI ≥ 27.5 kg/m2) to represent 
adult lean and adult overweight/obese patients, recognizing that 
patients who had an average a-BMI of 25-27.6 did have some 
excess mass (likely excess adiposity), but also noting that they 
were still at the lower end of the BMI range in this population. 
Adult lean patients who had stable BMI in adulthood (refer-
ence: a-BMI < 27.5 kg/m2 and ∆BMI 0-1.25 kg/m2; N = 53) 
had the best survival of all groups, whereas adult overweight/
obese patients who gained BMI in adulthood (N = 57) had the 
worst survival, with three times the all-cause hazard of death 
(Table 4). Compared to adult lean patients with stable BMI 
in adulthood, BMI loss in adulthood was associated with ap-
proximately 1.5 times hazard of death among both adult lean 
patients (N = 19) and adult obese patients (N = 56), though 
neither association was statistically significant (Table  4). 
However, when comparing only among adult obese patients 
(a-BMI ≥ 27.5 kg/m2), patients who lost BMI in adulthood 
(N = 56) had 0.69 times the all-cause hazard of death com-
pared against patients with stable BMI in adulthood (N = 58), 
though it was not statistically significant (95% CI 0.42, 1.11; 
P = .13). Including the six patients with d-BMI < 18.5 kg/m2 
in this analysis yielded similar results (Table S9).
4 |  DISCUSSION
To our knowledge, this is the first study to assess the associa-
tion of adult weight change prior to cancer onset with overall 
survival in EA patients. Adults who gained BMI throughout 
adulthood (∆BMI ≥ 1.25 kg/m2) had worse overall survival 
compared to patients who maintained stable BMI through-
out adulthood, independent of BMI at time of diagnosis and 
T A B L E  3  ΔBMI between average adult weight and weight 6 months prior to diagnosis and overall survival among EA patients (N = 285)
 
N 
events/
patients
Model 1 Model 2 Model 3
HRa 95% CI
P-
value
Global 
P-value HRb 95% CI
P-
value
Global 
P-value HRc 95% CI
P-
value
Global 
P-value
∆BMI categories (kg/m2)
Stable: >0 and 
≤1.25
72/111 Ref     .02d Ref     <.01d Ref     .01d 
BMI loss: <0 54/75 1.03 0.72; 
1.48
.87 0.98 0.68; 1.42 .92 1.04 0.72; 1.51 .83
BMI gain: 
≥1.25
73/99 1.53 1.09; 
2.14
.01 1.76 1.23; 2.54 <.01 1.68 1.17; 2.43 <.01
d-BMI (kg/m2)
≥18.5≥ and <25 61/81         Ref        <.01e   Ref        <.01e  
≥25 and <30 88/129         0.51 0.36; 0.73 <.01 0.54 0.38; 0.79 <.01
≥30 and <35 36/58         0.49 0.31; 0.77 <.01 0.54 0.34; 0.86 <.01
≥35 14/17         0.83 0.43; 1.60 .59 0.95 0.49; 1.85 .89
% body weight 
loss 6-mo prior to 
diagnosise
                  1.02 1.00; 1.04 .03  
Abbreviation: BMI, body mass index.
aModel 1: adjusted for sex, age at diagnosis, smoking status, treatment, and year of diagnosis. The model's baseline hazard was stratified by lymph node status, and 
surgery was coded as a time-dependent covariate. 
bModel 2: additionally adjusted for d-BMI. 
cModel 3: additionally adjusted for percent body weight loss 6 mo before diagnosis. 
dGlobal Wald test with 2 df. 
eGlobal Wald test with 3 df. Due to the small numbers, patients with BMI < 18.5 kg/m2 (N = 6) were excluded from these analyses. 
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percent weight loss in the 6 months prior to diagnosis. BMI 
loss in adulthood prior to disease onset (∆BMI < 0 kg/m2) 
was not associated with poorer survival compared to patients 
who maintained stable BMI throughout adulthood. These re-
sults suggest no benefit of accumulating or maintaining fat 
stores prior to the disease process; if additional fat stores 
causally improve survival, gaining additional fat in adulthood 
should improve survival, particularly among lean patients.
Consistent with previous studies that examined only 
d-BMI and weight loss leading up to diagnosis, we found that 
patients with BMI ≥ 25.0 and <35 kg/m2 at the time of diag-
nosis (d-BMI) had an decreased hazard of all-cause mortal-
ity compared to patients with d-BMI 18.5-25 kg/m2 15-19 and 
weight loss in the 6 months before diagnosis11,22,24,29 was also 
associated with an increased hazard of all-cause mortality. 
Accounting for ∆BMI did not attenuate these associations. 
Yet, because weight loss only in the 6  months prior to di-
agnosis, but not previous weight loss, was associated with 
poorer survival, the remaining observed association between 
d-BMI  <  25  kg/m2 and overall survival is likely capturing 
overall poor health status and complex unaccounted clinical 
factors (reverse causation and residual confounding).
Still, early life obesity and weight gain may biologically 
influence esophageal adenocarcinoma prognosis differently 
than BMI at the time of diagnosis. Given the invasive and 
aggressive treatment of esophageal adenocarcinoma, we can-
not rule out that higher BMI at the time of diagnosis has a 
biological survival advantage which may contrast from the 
effects of prediagnosis BMI.
Notably, lean adult patients who had stable BMI through-
out adulthood had the lowest hazard rate of all groups. Among 
both a-BMI < 27.5 kg/m2 and a-BMI ≥ 27.5 kg/m2, we ob-
served that BMI gain (∆BMI  ≥  1.25  kg/m2) in adulthood 
was associated with increased hazard of death compared to 
patients with stable BMI. Though we cannot determine the 
underlying causal mechanisms of the association, one hypoth-
esis is that BMI gain in adulthood (at all weights) confers a 
risk of a more aggressive tumor subtype, leading to poorer 
survival outcomes postdiagnosis. Among only patients with 
a-BMI ≥ 27.5 kg/m2, those who lost BMI in adulthood had 
a seemingly better survival compared to patients with stable 
BMI in adulthood, though the difference was not statistically 
significant. One cautious interpretation of this observation 
is that BMI loss among patients with a-BMI  ≥  27.5  kg/m2 
may represent a mix of patients with residual disease-related 
weight loss (deleterious) and patients with intentional weight 
loss (beneficial). Additionally, patients with a-BMI ≥ 27.5 kg/
m2 who had stable BMI or BMI gain in adulthood may be 
more likely than other subgroups to experience continued acid 
reflux, which could contribute to cancer progression in these 
patients. Ultimately, our findings highlight the insufficiency 
of using d-BMI alone to conclude that higher weight at diag-
nosis reflects a benefit for patient prognosis.
We could not take into account body composition in this 
study. We used BMI as a proxy for adiposity, but BMI is cor-
related less with adiposity in the elderly or in cancer patients, 
who both have tendencies for sarcopenia (low lean muscle 
mass).30,31 Moreover, the decline of muscle mass with aging 
seems to be steeper among men than women,32-35 though 
this may be mitigated by physical activitity.35 Sarcopenia is 
associated with both cachexia, a cancer-wasting syndrome, 
and with poor survival in cancer.26,36,37 Accounting for the 
T A B L E  4  Interaction between ΔBMI 
and average adult BMI and overall survival 
among EA patients (N = 285)
∆BMI 
categories 
(kg/m2)  
N events/
patients HRa 95% CI
P-
value
Interaction 
P-valueb 
Stable: ≥0 
and <1.25
a-BMI < 27.5 29/53 Ref     .10
BMI loss: <0 17/19 1.48 0.80; 2.77 .21
BMI gain: 
≥1.25
31/42 2.59 1.44; 4.66 <.01
Stable: ≥0 
and <1.25
a-BMI ≥ 27.5 43/58 2.24 1.24; 4.04 <.01
BMI loss: <0 37/56 1.54 0.90; 2.62 .11
BMI gain: 
≥1.25
42/57 3.05 1.62; 5.72 <.01
Abbreviation: BMI, body mass index.
aAdjusted for sex, age at diagnosis, smoking status, treatment, year of diagnosis, diagnosis BMI, percent body 
weight lost within the 6 mo before diagnosis. The baseline hazard was stratified by lymph node status, and 
surgery was coded as a time-dependent covariate. 
bWald test P-value for interaction term. Due to small numbers, patients with BMI < 18.5 kg/m2 (N = 6) were 
excluded from these analyses. 
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proportion of adiposity and lean muscle mass in patients is 
important to assess the driving mechanisms in the associa-
tion with mass and survival in EA. However, studies of sar-
copenia and survival in esophageal cancer to date have also 
relied largely on postdiagnosis measurements and changes, 
so these baseline measurements still do not account for pre-
diagnosis change in body composition. Our results should 
add caution by emphasizing that metrics of body mass at the 
time of diagnosis, no matter how sophisticated, may be mis-
leading if we do not account for the path of how the person 
attained their weight. Due to the primary study on the prog-
nostic value of body composition after diagnosis, it remains 
unclear whether body composition in a person's adult life 
prior to disease onset effects cancer prognosis through the 
same mechanism as observed postdiagnosis. Studies of pre-
diagnostic body composition with adult weight change in EA 
may prove particularly useful in elucidating metabolic mech-
anisms influencing cancer outcomes and identifying patients 
at risk of cachexia earlier in their clinical course.
Although nearly 30% of our population was missing infor-
mation on a-BMI, we found no difference in overall survival 
and found similar associations between d-BMI and overall 
survival for patients who did and did not report earlier life 
BMI measures, lowering the concern for selection bias. We 
relied on self-reported prediagnostic average adult weight and 
diagnostic weight. Though patients completed the question-
naire close to the time of diagnosis (median time after diagno-
sis 4.8 weeks), there may have been increased recall error the 
longer after diagnosis patients completed the questionnaire. 
d-BMI and reporting of weight loss in the 6 months prior to 
diagnosis are expected to be accurate.38-40 Studies have also 
shown that self-reported weight from previous times in life is 
fairly accurate,41-43 though obese patients may have greater 
misclassification of their early life-weight.42-44 Similarly, 
older patients had diluted average a-BMI values, since the 
average a-BMI value does not capture weight fluctuation in 
later adulthood. However, given EA's general clinical aggres-
siveness, age at diagnosis is not a strong predictor of overall 
survival, indicating this misclassification would have a weak 
impact on our association estimates. Additionally, we did not 
have information on cause-specific mortality, but due to the 
aggressive pattern of EA, we infer that the vast majority of 
patients in our study died from their cancer.
To our knowledge, we are the first to investigate the 
prognostic value of prediagnostic adult weight changes, in-
dependent of disease-related weight loss, in EA. We have a 
relatively large sample size of EA patients. In contrast to pre-
vious studies that used weight 1 year prior to diagnosis, we 
used average adult weight at least 5 years before diagnosis 
to reduce the possibility of disease-related changes with that 
measure. Additionally, unlike many clinical studies, we have 
thorough demographic and lifestyle data collected systemati-
cally for the purposes of research.
Our findings indicate that BMI gain in adulthood is associ-
ated with poor overall survival, and maintaining a normal body 
weight throughout adulthood is associated with the best overall 
survival among EA patients. Changes in BMI around the time 
of diagnosis likely reflect the consequences of the disease.
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